BACKGROUND AND PURPOSE: The purpose of this study was to derive quantitative parameters from magnetic resonance (MR) spectroscopic, perfusion, and diffusion imaging of grade 2 gliomas according to the World Health Organization and to investigate how these multiple imaging modalities can contribute to evaluating their histologic subtypes and spatial characteristics. MATERIALS AND METHODS: MR spectroscopic, perfusion, and diffusion images from 56 patients with newly diagnosed grade 2 glioma (24 oligodendrogliomas, 18 astrocytomas, and 14 oligoastrocytomas) were retrospectively studied. Metabolite intensities, relative cerebral blood volume (rCBV), and apparent diffusion coefficient (ADC) were statistically evaluated. RESULTS: The 75th percentile rCBV and median ADC were significantly different between oligodendrogliomas and astrocytomas (P < .0001) and between oligodendrogliomas and oligoastrocytomas (P < .001). Logistic regression analysis identified both 75th percentile rCBV and median ADC as significant variables in the differentiation of oligodendrogliomas from astrocytomas and oligoastrocytomas. Group differences in metabolite intensities were not significant, but there was a much larger variation in the volumes and maximum values of metabolic abnormalities for patients with oligodendroglioma compared with the other tumor subtypes. CONCLUSIONS: Perfusion and diffusion imaging provide quantitative MR parameters that can help to differentiate grade 2 oligodendrogliomas from grade 2 astrocytomas and oligoastrocytomas. The large variations in the magnitude and spatial extent of the metabolic lesions between patients and the fact that their values are not correlated with the other imaging parameters indicate that MR spectroscopic imaging may provide complementary information that is helpful in targeting therapy, evaluating residual disease, and assessing response to therapy.
BACKGROUND AND PURPOSE: The purpose of this study was to derive quantitative parameters from magnetic resonance (MR) spectroscopic, perfusion, and diffusion imaging of grade 2 gliomas according to the World Health Organization and to investigate how these multiple imaging modalities can contribute to evaluating their histologic subtypes and spatial characteristics. MATERIALS AND METHODS: MR spectroscopic, perfusion, and diffusion images from 56 patients with newly diagnosed grade 2 glioma (24 oligodendrogliomas, 18 astrocytomas, and 14 oligoastrocytomas) were retrospectively studied. Metabolite intensities, relative cerebral blood volume (rCBV), and apparent diffusion coefficient (ADC) were statistically evaluated. RESULTS: The 75th percentile rCBV and median ADC were significantly different between oligodendrogliomas and astrocytomas (P < .0001) and between oligodendrogliomas and oligoastrocytomas (P < .001). Logistic regression analysis identified both 75th percentile rCBV and median ADC as significant variables in the differentiation of oligodendrogliomas from astrocytomas and oligoastrocytomas. Group differences in metabolite intensities were not significant, but there was a much larger variation in the volumes and maximum values of metabolic abnormalities for patients with oligodendroglioma compared with the other tumor subtypes. CONCLUSIONS: Perfusion and diffusion imaging provide quantitative MR parameters that can help to differentiate grade 2 oligodendrogliomas from grade 2 astrocytomas and oligoastrocytomas. The large variations in the magnitude and spatial extent of the metabolic lesions between patients and the fact that their values are not correlated with the other imaging parameters indicate that MR spectroscopic imaging may provide complementary information that is helpful in targeting therapy, evaluating residual disease, and assessing response to therapy.
Authors: D Vigneron; A Bollen; M McDermott; L Wald; M Day; S Moyher-Noworolski; R Henry; S Chang; M Berger; W Dillon; S Nelson Journal: Magn Reson Imaging Date: 2001-01 Impact factor: 2.546
Authors: Isabelle Catalaa; Roland Henry; William P Dillon; Edward E Graves; Tracy R McKnight; Ying Lu; Daniel B Vigneron; Sarah J Nelson Journal: NMR Biomed Date: 2006-06 Impact factor: 4.044
Authors: M Rijpkema; J Schuuring; Y van der Meulen; M van der Graaf; H Bernsen; R Boerman; A van der Kogel; A Heerschap Journal: NMR Biomed Date: 2003-02 Impact factor: 4.044
Authors: Michael D Jenkinson; Trevor S Smith; Andrew R Brodbelt; Kathy A Joyce; Peter C Warnke; Carol Walker Journal: J Magn Reson Imaging Date: 2007-12 Impact factor: 4.813
Authors: Yi Sui; He Wang; Guanzhong Liu; Frederick W Damen; Christian Wanamaker; Yuhua Li; Xiaohong Joe Zhou Journal: Radiology Date: 2015-06-02 Impact factor: 11.105
Authors: Esin Ozturk-Isik; Andrea Pirzkall; Kathleen R Lamborn; Soonmee Cha; Susan M Chang; Sarah J Nelson Journal: Transl Oncol Date: 2012-02-01 Impact factor: 4.243
Authors: M A Prah; S M Stufflebeam; E S Paulson; J Kalpathy-Cramer; E R Gerstner; T T Batchelor; D P Barboriak; B R Rosen; K M Schmainda Journal: AJNR Am J Neuroradiol Date: 2015-06-11 Impact factor: 3.825
Authors: Kevin Leu; Garrett A Ott; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; William H Yong; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson Journal: J Neurooncol Date: 2017-05-25 Impact factor: 4.130
Authors: Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán Journal: Transl Oncol Date: 2013-12-01 Impact factor: 4.243